Impact of Variants on Elasomeran Mechanism

How do updated formulations (variants of concern) affect the mechanism of Elasomeran?

Updated mRNA-1273 formulations shift the neutralizing antibody response toward enhanced variant-specific recognition while maintaining the core B cell memory and T cell activation mechanisms of the original vaccine platform, with bivalent versions balancing variant-targeted depth against cross-reactive breadth.

Abstract

Updated mRNA-1273 formulations targeting SARS-CoV-2 variants of concern alter the immune response mechanism through differential neutralizing antibody profiles while maintaining the platform’s core immunological pathways. Monovalent variant-specific vaccines (mRNA-1273.351 targeting B.1.351, mRNA-1273.529 targeting BA.1) demonstrated superior neutralizing antibody responses against their target variants, with geometric mean ratios of 1.67-1.77 for BA.1 formulations and twofold improvements for B.1.351 formulations, but showed reduced cross-reactivity against ancestral strains with fourfold lower neutralization against WA1/2020 D614G. Bivalent formulations (mRNA-1273.211, mRNA-1273.214) balanced this trade-off by maintaining or improving ancestral strain neutralization (GMR 1.11 against D614G for BA.1-bivalent) while achieving GMT ratios ≥1 against all variants of concern tested. All updated formulations induced robust anamnestic B cell memory responses when used as boosters, with variant-modified boosters showing 34.9-61.6 fold increases in neutralization against target variants, restoring immunity that had waned 6-7 fold against wild-type and 24-69 fold against variants over 6 months. Cellular immune mechanisms, including CD4+ and CD8+ T cell responses measured in preclinical models, showed similar activation patterns to the original vaccine, with effector T cell expansion but not effector-memory phenotypes and waning within 6 months. However, longitudinal studies revealed progressive viral escape from updated vaccine-induced immunity, with newer variants continuing to evade even XBB.1.5-updated formulations, indicating that antigenic drift outpaces the vaccine update cycle despite mechanistic improvements in neutralizing breadth and depth.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Screening Criteria

• Vaccine Type and Formulation: Investigating Elasomeran (mRNA-1273) updated formulations targeting SARS-CoV-2 variants of concern?
• Mechanistic Outcomes: Reporting mechanistic outcomes including immunogenicity, antibody responses, T-cell responses, and vaccine efficacy?
• Comparative or Descriptive Data: Providing comparative data between updated formulations and original formulations?
• Study Design: Randomized controlled trial, cohort study, or other rigorous designs?
• Updated Formulation Focus: Investigating updated variants?
• Elasomeran Relevance: Investigating Elasomeran or comparisons to it?
• Mechanistic Data Inclusion: Including mechanistic investigations?
• Study Rigor: Full research articles with detail?

Data Extraction

Updated Formulation

• Specific vaccine name/code: mRNA-1273.351, mRNA-1273.211
• Variant(s) targeted: B.1.351, BA.1
• Type of formulation: Monovalent variant-specific and bivalent original+variant
• Dose amount: 50 μg

Immunological Mechanisms

• Neutralizing antibodies: Pseudovirus neutralization assays
• T-cell responses: CD4+, CD8+ T-cell responses measured through IFN-γ production

Variant Testing Panel

• Ancestral strain: D614G
• Variants of concern tested: B.1.351, BA.1

Comparative Mechanism Results

• Geometric mean titers/ratios with confidence intervals, fold-change differences in antibody levels

Vaccination Regimen

• Primary series: 2-dose series
• Booster dose administration

Breakthrough Protection

• Data on breakthrough infection rates by variant

Study Population

• Age groups studied: Adults
• Prior SARS-CoV-2 infection status

Mechanism Durability

• Time points measured and antibody waning rates

Results

Characteristics of Included Studies

The systematic review identified 10 sources examining updated mRNA-1273 formulations targeting SARS-CoV-2. Full texts were available for 6 studies.

Effects of Updated Formulations

Superiority Against Homologous Variants

Updated formulations demonstrated superior neutralizing antibody responses against their target variants compared to the original mRNA-1273 vaccine.

Cross-Variant Protection

Updated formulations maintained varying levels of cross-protection against non-target variants.

Booster Effects on Waning Immunity

Booster doses restored and enhanced neutralizing antibody titers that had declined over time.

Synthesis

The findings reveal systematic patterns in how updated mRNA-1273 formulations alter immunological mechanisms, with trade-offs based on specific variant targets. Monovalent vaccines demonstrate improved neutralization against specific variants while bivalent vaccines maintain broader protection against multiple strains.